Monitor Phase 2a enrollment updates and preliminary data readout expected in Q4 2026. The $20M SEPA introduces potential dilution; watch for drawdowns. Cash runway appears limited given clinical spend, so additional financing may be needed.
Price Chart
Executive Summary
Transcode Therapeutics filed an 8-K furnishing an investor presentation that updates on its pipeline, including Phase 1a data for lead candidate TTX-MC138 (no DLTs, 64% stable disease in evaluable patients) and initiation of Phase 2a enrollment in colorectal cancer. The presentation also details recent corporate developments: acquisition of Polynoma, a $25M investment by CK Life Sciences, licensing of an immuno-oncolytic portfolio, and a $20M SEPA with Yorkville Advisors. The company has $12.8M cash and no long-term debt, but faces dilution from the SEPA and preferred share conversion.
Key Facts
- Phase 1a TTX-MC138: 16 patients treated, 0 DLTs, 64% stable disease (9/14 evaluable), 3 patients remain on study.
- Phase 2a enrollment initiated in ctDNA+ colorectal cancer (N=45, single arm, 4.8 mg/kg Q28D).
- Cash and equivalents $12.8M as of March 31, 2026; no long-term debt.
- Pro forma shares outstanding 18.655M (including conversion of Series A, B, C preferred).
- Recent financings: $25M Series B from CK Life Sciences, $20M SEPA with Yorkville Advisors.
- Market capitalization ~$5.4M as of June 11, 2026 (current shares 950K).
Financial Impact
No revenue or earnings reported; cash position $12.8M; potential dilution from SEPA and preferred conversion (pro forma shares increase ~20x).
Risk Factors
- Dilution from SEPA and conversion of preferred shares (pro forma shares 18.7M vs 950K current).
- Clinical trial risks: Phase 2a data may not replicate Phase 1a safety/efficacy.
- Need for additional capital to fund operations beyond current cash.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-075440 |
| Document: tm2618153d1_8k.htm | 0001104659-26-075440 |
| Document: 0001104659-26-075440-index-headers.html | 0001104659-26-075440 |
| Document: 0001104659-26-075440-index.html | 0001104659-26-075440 |
| Document: 0001104659-26-075440.txt | 0001104659-26-075440 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | 8-K | $1.71 $1.71 | ▼ −0.26% | ▼ −0.23% | $1.71 (−0.23%) |
Sep 21, 2026 5w ago | 3 | $1.77 $1.68 | ▼ −5.08% | ▼ −4.52% | $1.71 (−3.62%) |
Sep 11, 2026 6w ago | 8-K | $1.65 $1.63 | ▲ +1.21% | ▲ +3.48% | $1.71 (−3.39%) |
Jul 2, 2026 16w ago | 8-K | $8.61 $4.22 | ▼ −50.99% | ▼ −51.84% | $1.71 (−80.19%) |
Jun 18, 2026 18w ago | 8-K | $4.70 $8.27 | ▲ +75.96% | ▲ +75.42% | $1.71 (−63.70%) |
Jun 3, 2026 20w ago | 8-K | $5.04 $8.61 | ▲ +70.83% | ▲ +71.83% | $1.71 (−66.15%) |
May 26, 2026 21w ago | DEFA14A | $5.39 $4.94 | ▲ +8.35% | ▲ +6.40% | $1.71 (+68.35%) |
Apr 30, 2026 25w ago | S-3 | $7.83 $5.44 | ▲ +30.59% | ▲ +35.85% | $1.71 (+78.21%) |
Apr 7, 2026 28w ago | 8-K | $8.70 $7.74 | ▲ +11.03% | ▲ +20.82% | $1.71 (+80.39%) |
Mar 3, 2026 33w ago | DEFA14A | $9.84 $8.69 | ▼ −11.69% | ▼ −7.27% | $1.71 (−82.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers